Alnadhari Ibrahim, Alshrani Muammer, Alhattami Asim, Shanaa Walid, Ali Omar, Abdeljaleel Osama, Abukhadijah Hana J, Shamsodini Ahmad
Department of Surgery, Urology Section, Al Wakra Hospital, Hamad Medical Corporation, Doha, Qatar.
Department of Surgery, Qatar University, Doha, Qatar.
Urol Res Pract. 2025 Jun 4;51(2):66-69. doi: 10.5152/tud.2025.25020.
Objective: The drug (paclitaxel)-coated balloon (DCB) Optilume® is designed to dilate the urethral lumen via balloon dilation while also promoting long-term urethral patency through the targeted and circumferential delivery of paclitaxel. As an antimitotic agent, paclitaxel functions by inhibiting cellular proliferation and migration. The objective of this study is to assess the safety and efficacy of this DCB in managing bulbar urethral strictures. Methods: This study is a retrospective study, involving 19 patients who underwent treatment with DCB for bulbar strictures. Patients' characteristics, preoperative and postoperative maximum flow rates (Qmax), and the duration until recurrence were recorded. Postoperative complications were also noted. Results: Success was achieved in 15 out of 19 patients (78.9%) with a median follow up period of 352 days. The mean maximum urine flow rate preoperatively was 5 mL/s (with a range of 4.00-6.50 mL/s). Subsequent mean flow rates at 3 months, 6 months, 12 months, and 24 months post-treatment were 32 mL/s, 32 mL/s, 24 mL/s, and 20 mL/s, respectively. Notably, there was no recurrence among the 7 patients without previous surgical interventions (47%, P-value .01). The mean duration of stricture-free survival following surgery was 648 days (approximately 21.6 months) (95% CI 500.4-700.2). Importantly, no complications were reported throughout the study. Conclusion: The use of DCB for managing bulbar urethral stricture demonstrated a success rate of 78.9%. Patients without a history of urethral surgery exhibited significantly improved treatment outcomes. Furthermore, the study reported no significant complications associated with the use of DCB.
药物（紫杉醇）涂层球囊（DCB）Optilume®旨在通过球囊扩张来扩张尿道腔，同时通过紫杉醇的靶向和周向递送促进尿道长期通畅。作为一种抗有丝分裂剂，紫杉醇通过抑制细胞增殖和迁移发挥作用。本研究的目的是评估这种DCB治疗球部尿道狭窄的安全性和有效性。方法：本研究是一项回顾性研究，纳入了19例接受DCB治疗球部狭窄的患者。记录患者的特征、术前和术后最大尿流率（Qmax）以及复发前的持续时间。还记录了术后并发症。结果：19例患者中有15例（78.9%）治疗成功，中位随访期为352天。术前平均最大尿流率为5 mL/s（范围为4.00 - 6.50 mL/s）。治疗后3个月、6个月、12个月和24个月的后续平均尿流率分别为32 mL/s、32 mL/s、24 mL/s和20 mL/s。值得注意的是，7例既往无手术干预的患者未出现复发（47%，P值为0.01）。术后无狭窄生存期的平均持续时间为648天（约21.6个月）（95%置信区间为500.4 - 700.2）。重要的是，整个研究期间未报告并发症。结论：使用DCB治疗球部尿道狭窄的成功率为78.9%。无尿道手术史的患者治疗效果显著改善。此外，该研究报告使用DCB未出现显著并发症。
